“Tak Perlu Gimik, Demo Lagu Sudah Ditonton 3 Juta”

Bulan lalu, penyanyi remaja popular Haqiem Ruslimengejutkan peminatnya apabila dia mengeluarkan kenyataan bakal bersara sebagai penyanyi selepas mengalami kemurungan teruk. Biogen Soars on Alzheimer's Drug Trial Success By Daniel Liberto | Updated July 6, 2018 — 4:47 AM EDT SHARE ADD TO WATCHLIST BIIB Biogen Inc 343.13 +14.83% View Watchlist Biogen Inc. (BIIB BIIB Biogen Inc 343.13 +14.83% ) and Eisai Co. have announced that their experimental Alzheimer’s drug successfully passed a mid-stage clinical trial. In a joint statement, the two companies said the highest dose of the drug, codenamed BAN2401, significantly slowed progression of the memory-robbing disease after 18 months of treatment, compared to a placebo. The trial, which tested 856 patients with the earliest stage of Alzheimer’s, known as mild cognitive impairment, included five dose regimens. News that Cambridge, Massachusetts-based Biogen and Japanese pharmaceutical group Eisai made an important breakthrough in the difficult field of Alzheimer’s research was well received by investors. Biogen’s shares rose 11.27% in pre-market trading, while Eisai’s valuation soared 19.47% in Tokyo. “The prospect of being able to offer meaningful disease-modifying therapies to individuals suffering from this terrible disease is both exciting and humbling,” said Dr Alfred Sandrock, executive vice-president and chief medical officer at Biogen. “These BAN2401 18-month data offer important insights in the investigation of potential treatment options for patients with Alzheimer’s disease and underscores that neurodegenerative diseases may not be as intractable as they once seemed.” Biogen and Eisai added that the full results of the mid-stage trial will be released at future conferences. The two companies also did not reveal plans for the Phase III trials, the final stage of testing before a medicine is approved. According to the Financial Times, many Alzheimer’s drugs have historically failed at the final hurdle. Last December, Biogen claimed that the drug was undergoing further tests as it had so far failed to meet its main goal in the mid-stage trial. (See also: Biogen's Big Stock Rally May Fizzle.) BAN2401 is one of many treatments seeking to target beta amyloid, a protein that forms toxic brain plaques responsible for causing Alzheimer’s. At present, drugs that target the disease are only capable of easing some of its symptoms, reported Reuters. (See also: 3 Big Biotech Stocks That Can Beat the Market.) Read more: Biogen Soars on Alzheimer's Drug Trial Success | Investopedia https://www.investopedia.com/news/biogen-soars-alzheimer-drug-trial-success/#ixzz5KUFcTlQs Follow us: Investopedia on Facebook

Share this post